Corral Alaejos A, Zarzuelo Castaneda A, Jimenez Cabrera S, Sanchez-Guijo F, Otero MJ, Perez-Blanco JS. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol. 2022;88(4):1913–24.

Article  PubMed  CAS  Google Scholar 

Sibieude E, Khandelwal A, Girard P, Hesthaven JS, Terranova N. Population pharmacokinetic model selection assisted by machine learning. J Pharmacokinet Pharmacodyn. 2022;49(2):257–70.

Article  PubMed  Google Scholar 

Chan A, Peck R, Gibbs M, van der Schaar M. Synthetic model combination: a new machine-learning method for pharmacometric model ensembling. CPT Pharmacometrics Syst Pharmacol. 2023;12(7):953–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, Wicha SG. A model averaging/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109(1):175–83.

Article  PubMed  CAS  Google Scholar 

Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes D, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33(10):1071–82.

Article  PubMed  CAS  Google Scholar 

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

Article  PubMed  CAS  Google Scholar 

Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361–4.

Article  PubMed  CAS  Google Scholar 

Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53(4):305–25.

Article  PubMed  CAS  Google Scholar 

Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201.

Article  PubMed  CAS  Google Scholar 

van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW. Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors. Pharmaceuticals (Basel). 2021;14(2):119.

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935–42.

Article  PubMed  CAS  Google Scholar 

Vancomycin Summary of product characteristics Date last accessed: 13 December 2023; Available from: https://www.medicines.org.uk/emc/product/8759/smpc/print.

Zhao S, He N, Zhang Y, Wang C, Zhai S, Zhang C. Population pharmacokinetic modeling and dose optimization of vancomycin in Chinese patients with augmented renal clearance. Antibiotics (Basel). 2021;10(10):1238.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin. 2018;39(2):286–93.

Article  PubMed  CAS  Google Scholar 

Dolton M, Xu H, Cheong E, Maitz P, Kennedy P, Gottlieb T, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns. 2010;36(4):469–76.

Article  PubMed  Google Scholar 

Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, Claeys KC, et al. Vancomycin pharmacokinetics in obese patients with sepsis or septic shock. Pharmacotherapy. 2020;40(3):211–20.

Article  PubMed  CAS  Google Scholar 

Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447–54.

Article  PubMed  CAS  Google Scholar 

Fu X, Lin L, Huang L, Guo L. Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia. Biopharm Drug Dispos. 2021;42(9):427–34.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767–80.

Article  PubMed  CAS  Google Scholar 

Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55(6):2704–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol. 2006;61(2):164–76.

Article  PubMed  CAS  Google Scholar 

Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, Fernandez de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201–12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vu DH, Nguyen DA, Delattre IK, Ho TT, Do HG, Pham HN, et al. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulations for improved dosing schemes. Int J Antimicrob Agents. 2019;54(6):702–8.

Article  PubMed  CAS  Google Scholar 

Medellin-Garibay SE, Ortiz-Martin B, Rueda-Naharro A, Garcia B, Romano-Moreno S, Barcia E. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471–9.

Article  PubMed  CAS  Google Scholar 

Smit C, Wasmann RE, Goulooze SC, Wiezer MJ, van Dongen EPA, Mouton JW, et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 2020;86(2):303–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bang JY, Kang HI, Lee HJ, Chong YP, Hong SK, Lee EK, et al. Development of a new pharmacokinetic model for target-concentration controlled infusion of vancomycin in critically ill patients. Clin Exp Pharmacol Physiol. 2022;49(2):202–11.

Article  PubMed  CAS  Google Scholar 

Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127–39.

Article  PubMed  CAS  Google Scholar 

Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, Roberts JA. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents. 2013;41(6):564–8.

Article  PubMed  CAS  Google Scholar 

Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63(5):1050–7.

Article  PubMed  CAS  Google Scholar